Skip to main content
Premium Trial:

Request an Annual Quote

XDx's AlloMap Gets Positive Determination from Aetna

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Aetna has determined that the firm's AlloMap test is medically necessary for monitoring rejection in heart transplant recipients more than a year after a heart transplant.

"Recognition of AlloMap's benefit for eligible heart transplant recipients by one of the leading providers of health care in the United States is an important validation of our tests and results," Pierre Cassigneul, president and CEO of Brisbane, Calif.-based XDx, said in a statement. "We hope to reduce the number of invasive biopsies that stable patients have to undergo post-transplant and thereby improve patients' quality of life."

XDx received US Food and Drug Administration clearance for AlloMap in 2008. The test is a non-invasive, multi-gene expression assay used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with a standard clinical assessment.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.